Our Company

Moleculin Biotech is a clinical stage pharmaceutical company focused on the treatment of highly resistant cancers and viruses.

Our lead program, Annamycin, is a next-generation anthracycline designed be non-cardiotoxic and to avoid the multidrug resistance mechanisms that typically defeat currently approved anthracyclines. Annamycin has preliminary clinical data suggesting its potential to become the first successful therapy suitable for the majority of relapsed or refractory acute myeloid leukemia (AML) patients and is currently in development for the treatment of relapsed or refractory AML and soft tissue sarcoma (STS) lung metastases.

Additionally, we are developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma.

We are also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.

Our Commitment

Better Treatments, More Tomorrows

We are committed to solving the toughest challenges in highly resistant cancers and viruses. Through our extensive network of world-renowned research organizations, we aim to develop better treatments that can make a real impact in people’s lives.